...evidence was "unreliable." The evidence Johnson & Johnson submitted came from the single-arm Phase III SIRIUS...

...POC Medical raised $21 million in a series A round led by BioVentures Investors . Sirius...

...and an immunomodulatory agent (IMiD). The recommendation was based on data from the Phase III SIRIUS...

...the drug has not yet been approved. The BLA included data from the Phase II Sirius...

...3 stringent complete responses, 10 very good PRs and 18 PRs in the Phase II Sirius...

...against CD38 (see BioCentury, Sept. 3, 2012). Both applications include data from the Phase II Sirius...

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...

...Data from 106 MM patients in the 2-part, open-label, international Phase II Sirius MMY2002 trial showed...

...Preliminary data from the 2-part, open-label, international Phase II Sirius MMY2002 trial in 124 MM patients...